J. Houbiers

发表

National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) symptom evaluation in multinational cohorts of patients with chronic prostatitis/chronic pelvic pain syndrome.

J. Nickel, G. Perletti, V. Magri, 2013, European urology.

Decrease of disease activity under ineffective therapy in DMARD-naive patients with early rheumatoid arthritis: role of antibody profiles and carriage of the HLA shared epitope in predicting decrease of disease activity.

A. Boots, F. E. Van den Bosch, F. de Keyser, 2007, The Journal of rheumatology.

Synovial inflammation does not change in the absence of effective treatment: implications for the use of synovial histopathology as biomarker in early phase clinical trials in rheumatoid arthritis

A. Boots, E. Veys, F. Keyser, 2006, Annals of the rheumatic diseases.

phase clinical trials in rheumatoid arthritis use of synovial histopathology as biomarker in early absence of effective treatment: implications for the Synovial inflammation does not change in the

A. Boots, F. Bosch, E. Kruithof, 2006 .

In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53

S. H. van der Burg, J. Drijfhout, W. Kast, 1993, European journal of immunology.

A combined proof of concept and dose finding study with multiple endpoints: A Bayesian adaptive design in chronic prostatitis/chronic pelvic pain syndrome

R. Martina, J. Houbiers, J. Melis, 2018, Biometrical journal. Biometrische Zeitschrift.

Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trial

F. Breedveld, L. V. D. van de Putte, D. M. van der Heijde, 2009, Annals of the rheumatic diseases.

Intranasal administration of recombinant human cartilage glycoprotein-39. A phase I escalating cohort study in patients with rheumatoid arthritis.

L. V. D. van de Putte, P. V. van Riel, F. V. D. van den Hoogen, 2006, The Journal of rheumatology.

Endogenous HLA-DR-restricted presentation of the cartilage antigens human cartilage gp-39 and melanoma inhibitory activity in the inflamed rheumatoid joint.

J. Vencovský, F. V. D. van den Hoogen, A. Boots, 2007, Arthritis and rheumatism.

Alefacept Combined With Tacrolimus, Mycophenolate Mofetil and Steroids in De Novo Kidney Transplantation: A Randomized Controlled Trial

L. Rostaing, P. Rigotti, B. Charpentier, 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Prostatic Diseases and Male Voiding Dysfunction Fatty Acid Amide Hydrolase Inhibitor Treatment in Men With Chronic Prostatitis / Chronic Pelvic Pain Syndrome : An Adaptive Double-blind , Randomized Controlled Trial

J. Nickel, D. Shoskes, M. Urban, 2017 .

The selective estrogen receptor alpha agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: a phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving stable background methotrexate or sulfasalazine.

B. Dijkmans, M. Boers, F. Buttgereit, 2010, Arthritis and rheumatism.

Identification of peptide sequences that potentially trigger HLA‐A2.1‐restricted cytotoxic T lymphocytes

S. H. van der Burg, J. Drijfhout, W. Kast, 1993, European journal of immunology.

Influence of infection on the distribution patterns of NIH-Chronic Prostatitis Symptom Index scores in patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)

G. Perletti, V. Magri, G. Petrikkos, 2013, Experimental and therapeutic medicine.

Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomised, placebo controlled, proof-of-concept study

J. Isaacs, P. Tak, D. Gerlag, 2011, Annals of the rheumatic diseases.

An adaptive randomized clinical trial in interstitial cystitis/bladder pain syndrome evaluating efficacy of ASP3652 and the relationship between disease characteristics and Hunner’s lesions

P. Hanno, J. Nickel, J. Nordling, 2020, World Journal of Urology.

Fatty Acid Amide Hydrolase Inhibitor Treatment in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: An Adaptive Double-blind, Randomized Controlled Trial.

J. Nickel, D. Shoskes, M. Urban, 2017, Urology.

The Burden of Bladder Pain in Five European Countries: A Cross-sectional Study.

J. Vietri, R. Pedersini, Z. Hakimi, 2017, Urology.

The expression of histocompatibility-related leukocyte antigens in the pathway to cervical carcinoma.

G. Fleuren, C. Hilders, J. Houbiers, 1994, American journal of clinical pathology.

Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial.

J. Hermans, A. Brand, P. J. van den Broek, 1998, Circulation.

Identification of peptide sequences that potentially trigger HLA‐A2.1‐restricted cytotoxic T lymphocytes

S. H. van der Burg, J. Drijfhout, W. Kast, 1993, European journal of immunology.

National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) symptom evaluation in multinational cohorts of patients with chronic prostatitis/chronic pelvic pain syndrome.

J. Nickel, G. Perletti, V. Magri, 2013, European urology.